Compounded Tirzepatide Cost: Advertised Prices and Cautions
Compounded tirzepatide is advertised from about $379 a month, well below the branded tirzepatide list prices. This page explains what that advertised figure does and does not include, why compounded products are not FDA approved, the difference between 503A and 503B pharmacies, and the FDA caution context to weigh before price decides anything.
The advertised price, stated plainly
Compounded tirzepatide cost is quoted on this site as about $379 a month as a typical advertised starting price. Starting price is the important phrase. Advertisements commonly lead with the price of the lowest dose or an introductory period, and the amount can rise as a dose rises or an introductory term ends. A monthly figure in an advertisement is a marketing entry point, not a quote for your dose for the whole course of treatment.
By simple multiplication of the stated monthly figure, about $379 multiplied by 12 is about $4,548 over 12 months. That annual figure is only that multiplication, shown for scale. It assumes the starting price held for a year, which advertisements do not guarantee. Before comparing it with a branded price, confirm what the compounded price includes, how it changes with dose, what the consultation and shipping arrangements are, and what happens to the price after any introductory period.
For context, the branded tirzepatide products sit at about $1,080 a month for Mounjaro and about $1,060 a month at approximate US list prices. The gap between those figures and about $379 is real as a price gap. The rest of this page is about why price is the only part of the comparison that is straightforward.
Compounded products are not FDA approved
Compounded tirzepatide is not FDA approved. That sentence should appear wherever the product is discussed, including here. Compounding is a pharmacy practice where a pharmacy prepares a medicine for an individual patient under a prescription, and compounded preparations do not go through the FDA approval process that branded Mounjaro and Zepbound went through for safety, effectiveness and manufacturing quality.
Not FDA approved does not automatically mean a preparation is unsafe, and FDA approved does not mean a medicine suits every patient. It does mean the assurance structure is different: the dose accuracy, purity, stability and consistency of a compounded preparation rest on the pharmacy and the oversight that applies to it, rather than on an approved product made to an approved specification. The FDA has published cautions about compounded GLP-1 products, including reports of dosing errors and of products using different salt forms of the ingredients, and those cautions are part of the context any buyer should read.
503A and 503B: the two compounding routes
US compounding generally sits in two categories. A 503A pharmacy compounds under a patient specific prescription, under state board of pharmacy oversight, typically in smaller, individual preparation. A 503B outsourcing facility registers with the FDA, can prepare larger batches without patient specific prescriptions in advance, and is inspected against federal manufacturing standards. The category affects the oversight structure behind the product you receive.
A careful buyer asks which category the supplying pharmacy is, whether it is licensed in their state, who the prescribing clinician is and how follow up works, and whether the pharmacy will state exactly what is in the preparation. A seller that cannot or will not answer those questions clearly is giving you useful information by that refusal. The compounded semaglutide guide on this site works through the same judgement questions for the related ingredient, and the reasoning transfers.
Why the price can be so much lower
The advertised price is lower for structural reasons. A compounded preparation is not the branded pen product: there is no manufacturer pen device, no approval programme cost behind it, and marketing commonly prices the starting dose to attract enrolment. Some offers bundle a telehealth consultation and the medicine in one subscription figure, which makes direct comparison with a pharmacy pen price harder still. None of that makes an offer good or bad on its own. It means the figures are not prices for the same thing.
Dosing format matters to value as well as to safety. Branded tirzepatide comes in pens built around set weekly doses, up to 15 mg weekly for Mounjaro and maintenance doses of 5, 10 or 15 mg weekly for Zepbound. Compounded products are commonly supplied in vials drawn with a syringe, where concentration can differ by pharmacy. That is why units on a syringe cannot be converted by a universal rule, and why only your prescriber or pharmacist can interpret your specific vial.
Using the numbers without letting them decide alone
Price is a legitimate part of a treatment decision, because an unaffordable branded medicine helps no one. The safe way to use the compounded figure is as one input among several: the advertised starting price of about $379 a month, the confirmation of what it becomes at your dose, the category and licensing of the pharmacy, the clinician follow up arrangements, and the FDA caution context, all weighed with your prescriber.
The compounded savings calculator on this site shows branded and compounded figures side by side over the months you choose, using the approximate prices used across GLPKit. Run it for the arithmetic, then do the non arithmetic checks this page describes before you treat the saving as real. If a seller pressures a fast decision, discourages questions, or offers the product without a prescription, walk away regardless of the price.
Finally, keep records of whatever you are supplied: the pharmacy name and category, the clinician who prescribed it, the concentration stated on the vial, and the price actually charged at each dose level. If anything changes between fills, ask why before using the new supply. Those basic records are what allow a prescriber or pharmacist to help you quickly if a dose feels wrong or a side effect appears.
Frequently asked questions
How much does compounded tirzepatide cost?
About $379 a month is the typical advertised starting price used across this site. Advertised prices commonly reflect the lowest dose or an introductory period and can rise with dose, so confirm the full price at your dose before comparing.
What is compounded tirzepatide over a year at the advertised price?
By simple multiplication of the stated monthly figure, about $379 multiplied by 12 is about $4,548 over 12 months. That assumes the starting price held all year, which advertisements do not guarantee.
Is compounded tirzepatide FDA approved?
No. Compounded tirzepatide is not FDA approved. Compounded preparations do not go through the FDA approval process for safety, effectiveness and manufacturing quality that branded Mounjaro and Zepbound completed.
What is the difference between 503A and 503B compounding?
A 503A pharmacy compounds against a patient specific prescription under state board oversight. A 503B outsourcing facility registers with the FDA and prepares larger batches under federal manufacturing standards and inspection. The category changes the oversight behind the product.
Why is compounded tirzepatide cheaper than Mounjaro or Zepbound?
It is a different product without the branded pen device or approval programme behind it, and advertisements commonly lead with a starting dose price, sometimes bundled with a consultation. The price gap is real, but the products are not equivalent.